Shanghai RAAS Blood Products Co Ltd Class A (002252) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai RAAS Blood Products Co Ltd Class A (002252) has a cash flow conversion efficiency ratio of -0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-30.25 Million ≈ $-4.43 Million USD) by net assets (CN¥32.58 Billion ≈ $4.77 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shanghai RAAS Blood Products Co Ltd Class A - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Shanghai RAAS Blood Products Co Ltd Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Shanghai RAAS Blood Products Co Ltd Clas (002252) financial obligations for a breakdown of total debt and financial obligations.
Shanghai RAAS Blood Products Co Ltd Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai RAAS Blood Products Co Ltd Class A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Keda Clean Energy Co Ltd
SHG:600499
|
0.094x |
|
Home BancShares Inc
NYSE:HOMB
|
0.030x |
|
TECHNOLOGY ONE LTD.
F:RW8
|
N/A |
|
Patanjali Foods Limited
NSE:PATANJALI
|
-0.048x |
|
GEM CO. LTD SP.GDR/10 A
F:3730
|
N/A |
|
PTC Therapeutics Inc
NASDAQ:PTCT
|
0.167x |
|
Sinopec Oilfield Service Corp
SHG:600871
|
0.100x |
|
Credit Acceptance Corporation
NASDAQ:CACC
|
0.197x |
Annual Cash Flow Conversion Efficiency for Shanghai RAAS Blood Products Co Ltd Class A (2005–2024)
The table below shows the annual cash flow conversion efficiency of Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see 002252 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥31.94 Billion ≈ $4.67 Billion |
CN¥-482.06 Million ≈ $-70.54 Million |
-0.015x | -119.64% |
| 2023-12-31 | CN¥29.65 Billion ≈ $4.34 Billion |
CN¥2.28 Billion ≈ $333.33 Million |
0.077x | +28.28% |
| 2022-12-31 | CN¥28.81 Billion ≈ $4.22 Billion |
CN¥1.73 Billion ≈ $252.51 Million |
0.060x | +19.89% |
| 2021-12-31 | CN¥25.90 Billion ≈ $3.79 Billion |
CN¥1.29 Billion ≈ $189.35 Million |
0.050x | +7.40% |
| 2020-12-31 | CN¥25.13 Billion ≈ $3.68 Billion |
CN¥1.17 Billion ≈ $171.04 Million |
0.047x | -38.76% |
| 2019-12-31 | CN¥11.49 Billion ≈ $1.68 Billion |
CN¥872.69 Million ≈ $127.70 Million |
0.076x | +215.13% |
| 2018-12-31 | CN¥10.89 Billion ≈ $1.59 Billion |
CN¥262.50 Million ≈ $38.41 Million |
0.024x | +13.52% |
| 2017-12-31 | CN¥12.48 Billion ≈ $1.83 Billion |
CN¥264.95 Million ≈ $38.77 Million |
0.021x | -60.98% |
| 2016-12-31 | CN¥11.73 Billion ≈ $1.72 Billion |
CN¥638.22 Million ≈ $93.39 Million |
0.054x | -23.55% |
| 2015-12-31 | CN¥10.71 Billion ≈ $1.57 Billion |
CN¥762.42 Million ≈ $111.57 Million |
0.071x | +31.73% |
| 2014-12-31 | CN¥8.62 Billion ≈ $1.26 Billion |
CN¥465.96 Million ≈ $68.18 Million |
0.054x | +166.06% |
| 2013-12-31 | CN¥1.10 Billion ≈ $161.22 Million |
CN¥-90.11 Million ≈ $-13.19 Million |
-0.082x | -131.65% |
| 2012-12-31 | CN¥1.02 Billion ≈ $149.18 Million |
CN¥263.46 Million ≈ $38.55 Million |
0.258x | +34.61% |
| 2011-12-31 | CN¥927.27 Million ≈ $135.69 Million |
CN¥178.03 Million ≈ $26.05 Million |
0.192x | -20.29% |
| 2010-12-31 | CN¥831.21 Million ≈ $121.63 Million |
CN¥200.21 Million ≈ $29.30 Million |
0.241x | +58.49% |
| 2009-12-31 | CN¥763.33 Million ≈ $111.70 Million |
CN¥116.01 Million ≈ $16.98 Million |
0.152x | +6.57% |
| 2008-12-31 | CN¥754.76 Million ≈ $110.45 Million |
CN¥107.64 Million ≈ $15.75 Million |
0.143x | -86.20% |
| 2007-12-31 | CN¥170.01 Million ≈ $24.88 Million |
CN¥175.71 Million ≈ $25.71 Million |
1.034x | +202.38% |
| 2006-12-31 | CN¥156.77 Million ≈ $22.94 Million |
CN¥53.58 Million ≈ $7.84 Million |
0.342x | +46.61% |
| 2005-12-31 | CN¥231.70 Million ≈ $33.90 Million |
CN¥54.02 Million ≈ $7.90 Million |
0.233x | -- |
About Shanghai RAAS Blood Products Co Ltd Class A
Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. The… Read more